- Home
- Publications
- Publication Search
- Publication Details
Title
EGFR-TKIs resistance via EGFR-independent signaling pathways
Authors
Keywords
EGFR, TKIs, RTKs, ErbB, Drug resistance, Bypass signalings, Downstream compounds
Journal
Molecular Cancer
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-02-15
DOI
10.1186/s12943-018-0793-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
- (2017) Jia Zhong et al. Journal of Thoracic Oncology
- IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
- (2017) Heming Li et al. Molecular Cancer
- Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
- (2017) Hatim Husain et al. MOLECULAR CANCER THERAPEUTICS
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment
- (2017) Qian Liu et al. TUMOR BIOLOGY
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- (2016) S. Ortiz-Cuaran et al. CLINICAL CANCER RESEARCH
- The CXCL8-CXCR1/2 pathways in cancer
- (2016) Qian Liu et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
- (2016) Qing Zhou et al. Journal of Hematology & Oncology
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Synthetic lethality in lung cancer and translation to clinical therapies
- (2016) Ada W. Y. Leung et al. Molecular Cancer
- Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma
- (2016) Guo Chen et al. JAMA Oncology
- EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
- (2015) D. Planchard et al. ANNALS OF ONCOLOGY
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
- (2015) Sara M. Tolaney et al. INVESTIGATIONAL NEW DRUGS
- Mechanisms of Acquired Resistance to AZD9291
- (2015) Tae Min Kim et al. Journal of Thoracic Oncology
- Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations
- (2015) Chang Dong Yeo et al. LUNG CANCER
- Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells
- (2015) D. Yarar et al. MOLECULAR CANCER THERAPEUTICS
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer
- (2015) E. L. Kwak et al. Cancer Discovery
- Targeting RTK Signaling Pathways in Cancer
- (2015) Tarik Regad Cancers
- METin ovarian cancer: Metastasis and resistance?
- (2014) Chad Tang et al. CELL CYCLE
- A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
- (2014) Jian Zhang et al. Journal of Hematology & Oncology
- Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
- (2014) Daniele Cretella et al. Molecular Cancer
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
- (2013) Kerstin Kampa-Schittenhelm et al. Molecular Cancer
- Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
- (2013) Hideki Terai et al. MOLECULAR CANCER RESEARCH
- Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer
- (2013) M. J. Niederst et al. Science Signaling
- Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
- (2013) Alberto Bardelli et al. Cancer Discovery
- Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
- (2012) Brigid C. Browne et al. BREAST CANCER RESEARCH AND TREATMENT
- Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
- (2012) A. B. Cortot et al. CANCER RESEARCH
- Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands
- (2012) Seiji Yano et al. CANCER SCIENCE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
- (2012) R M A Linger et al. ONCOGENE
- Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
- (2012) K. Ohashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition
- (2012) Ketan S. Gajiwala et al. STRUCTURE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Checks and balances: Interplay of RTKs and PTPs in cancer progression
- (2011) Sarita K. Sastry et al. BIOCHEMICAL PHARMACOLOGY
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification
- (2011) Sai-Hong Ignatius Ou et al. Journal of Thoracic Oncology
- Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
- (2011) Kenichi Suda et al. Journal of Thoracic Oncology
- A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network
- (2011) Shannon E. Telesco et al. Molecular BioSystems
- Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
- (2011) Amit Dutt et al. PLoS One
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor-Activating Mutations
- (2010) C. Yamamoto et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives
- (2010) Nicola et al. Frontiers in Bioscience-Landmark
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- (2010) J. Weiss et al. Science Translational Medicine
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
- (2009) T. Yamada et al. CLINICAL CANCER RESEARCH
- IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
- (2009) Federico Cappuzzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status
- (2009) Takamitsu Onitsuka et al. LUNG CANCER
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
- A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy
- (2008) S. T. Lee-Hoeflich et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- (2008) J. A. Engelman et al. CLINICAL CANCER RESEARCH
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations
- (2008) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of ErbB3 and its Binding Partners in Breast Cancer Progression and Resistance to Hormone and Tyrosine Kinase Directed Therapies
- (2008) Anne W. Hamburger JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
- Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
- (2008) Z. Wu et al. PROSTATE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now